P

Prothena Corp
D

PRTA

8.49000
USD
-0.22
(-2.53%)
مغلق
حجم التداول
319,552
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
456,991,077
أصول ذات صلة
ALNY
ALNY
3.98
(1.56%)
259.33 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
B
BLUE
-0.15000
(-3.69%)
3.91000 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
ILMN
ILMN
1.395
(1.82%)
77.905 USD
N
NTLA
0.20000
(2.32%)
8.83000 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
S
SGMO
-0.01210
(-1.63%)
0.72800 USD
المزيد
الأخبار المقالات

العنوان: Prothena Corp

القطاع: Healthcare
الصناعة: Biotechnology
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.